EDX Medical Group PLC EDX Medical Group PLC strengthens senior team
22 Juin 2023 - 8:00AM
RNS Non-Regulatory
TIDMEDX
EDX Medical Group PLC
22 June 2023
EDX Medical Group PLC strengthens senior team
EDX Medical Group Plc -- EDX
22 June 2023
EDX Medical Group PLC ("EDX Medical" or the "Company"), which
develops innovative digital diagnostic products and services
enabling cost effective and timely delivery of personalised
treatment for cancer, heart disease, neurology and infectious
diseases, today announces that Dr Keti Zeka will be joining the
senior management team as Head of R&D and Director of
Laboratories. Dr Liam Dower will join the senior management team as
Head of Quality, Regulatory Affairs & Compliance. Both will be
based at the Company's laboratory and head office in Cambridge,
UK.
Dr. Zeka is a highly experienced biochemist who holds a BSc and
MSc in Medical Biotechnology (cum Laude) and a PhD in Chemical
Engineering & Biotechnology Innovation from the University of
L'Aquila, Italy. Since 2017, she has held multiple prestigious
research fellowships at the University of Cambridge and University
College London, in addition to her commercial experience as the PCR
Team Lead at the National Covid-19 Testing Centre in Cambridge.
Dr Zeka commented :
"I'm delighted to join EDX Medical as this role provides the
opportunity for me to lead a team of exceptional scientists and
technologists focused on pioneering the use of digital diagnostics
for the benefit of patients."
Dr Dower holds a first class B.Eng and PhD from the Department
of Metallurgy & Engineering Materials, University of
Strathclyde along with a postgraduate certificate in Intellectual
Property management from Bournemouth University. He has previously
held product development, quality and regulatory posts at Johnson
& Johnson, Origin Sciences and Fluidic Analytics.
Dr Dower commented :
"I'm delighted to be able to bring my wide experience of the
regulated medical device sector to EDX Medical at this exciting
time in the company's growth."
Dr Mike Hudson, Chief Executive of EDX Medical Group PLC,
commented:
"We are thrilled to welcome Keti and Liam, where they will play
pivotal roles developing and delivering ISO-15189 accredited
laboratory services and ISO 13485 accredited point of care tests
for our clients in the clinical sector."
Contacts:
EDX Medical PLC
Dr Mike Hudson (Chief Executive Officer) +44 (0)7812 345 301
mike@edxmedical.co.uk
Oberon Capital
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith (Director) +44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen (Senior Consultant) + 44 (0)7834 694609
gary@mediahouse.co.uk
Notes for Editors:
About EDX Medical Group
www.edxmedical.co.uk
EDX Medical Group Plc develops innovative digital diagnostic
products and services, enabling cost effective and timely delivery
of personalised treatment for cancer, heart disease, neurology and
infectious diseases. The company is listed on the Access Segment of
the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE,
a medical and life sciences entrepreneur with more than 30 years of
experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to personalise treatment in a
timely fashion. Early disease detection and biologically-based
personal treatment optimisation is considered to be the most
impactful way of reducing deaths and lowering the cost of
healthcare globally.
EDX Medical Group operates a molecular biology and diagnostics
laboratory in Cambridge, UK, and a 100%-owned subsidiary "Torax
Biosciences Ltd" ( www.toraxbiosciences.co.uk ) in Ireland.
EDX Medical, provides testing and genomic sequencing services,
undertakes quality assurance, conducts research & development
(R&D) and has established expertise in the design, development,
validation and sourcing of diagnostic testing solutions to ISO
13485. Key laboratory tests performed by the Company have been
accredited to ISO 15189 by the United Kingdom Accreditation Service
(UKAS).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRANKDBPQBKDOAB
(END) Dow Jones Newswires
June 22, 2023 02:00 ET (06:00 GMT)
EDX Medical (AQSE:EDX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
EDX Medical (AQSE:EDX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024